On Aug. 5, Novavax (NASDAQ:NVAX) reported second-quarter earnings for 2021. They didn’t bode well for NVAX stock. Source: Ascannio/Shutterstock.com The company also provided some updates related to its vaccine against the Covid-19 pandemic. The markets clearly seemed to be unhappy and the stock plunged by 20% in the first trading session after results. However, it’s…